TriangleDISEASE & TREATMENT SETTING
Hernexeos: unresectable metastatic Non-small cell lung cancer with HER2 stated without a specific alteration, ERBB2 stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA approved test, and who have received prior systemic therapy
Broader topic: Non-Small Cell Lung Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- gene
- HER2
- alteration
- stated without a specific alteration
- status
- present
- gene
- ERBB2
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- who have received prior systemic therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Hernexeos (zongertinib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA approved test, and who have received prior systemic therapy
Study evidence for this setting
18F-FSPG PET/CT for Cancer Patients on Therapy
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice